AVE 0010

Known as: AVE-0010, AVE0010 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2017
01220082017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
OBJECTIVE To review the pharmacology, pharmacokinetics, efficacy, and safety of the glucagon-like peptide-1 receptor agonist (GLP… (More)
Is this relevant?
Review
2017
Review
2017
Circulation. 2017;136:1560–1562. DOI: 10.1161/CIRCULATIONAHA.117.029503 1560 Patients with a recent coronary event are at high… (More)
Is this relevant?
2015
2015
AIMS/INTRODUCTION This was a subanalysis of Japanese patients included in the glucagon-like peptide-1 receptor agonist AVE0010 in… (More)
  • table 1
  • figure 2
  • figure 1
  • table 2
Is this relevant?
2014
2014
Lixisenatide (AVE0010) is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes… (More)
Is this relevant?
2012
2012
RESEARCH DESIGN AND METHODSdRandomized, double-blind, 12-week study of 361 patients not on glucose-lowering therapy (HbA1c 7–10… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
2010
2010
AIMS To evaluate the dose-response relationship of lixisenatide (AVE0010), a glucagon-like peptide-1 (GLP-1) receptor agonist, in… (More)
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2008
2008
We recently showed that insulin analogues exhibit a beta-cell protective function. The aim of this study was to test if the anti… (More)
Is this relevant?
2008